Cyclic peptide ligands that target urokinase plasminogen activator receptor

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 6277818
SERIAL NO

09181816

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

uPAR-targeting cyclic peptide compounds have 11 amino acids that correspond to human uPA(20-30) [SEQ ID NO:2], or are substitution variants at selected positions. The N and C terminal residues of these peptides are joined by a linking group L, so that the linear dimension between the a carbons of the first and the eleventh amino acids is between about 4 and 12 .ANG.ngstrom units. These cyclic peptides may be further conjugated to diagnostic labels or therapeutic moieties such as radionuclides. Such compounds are usefull for targeting uPAR expressed in pathological tissues and for inhibiting the binding of uPA to the uPAR. The pharmaceutical and therapeutic compositions inhibit cell migration, cell invasion, cell proliferation or angiogenesis, or induce apoptosis, and are thus useful for treating diseases or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, most notably cancer. The cyclic peptides are also used to detect and isolate cells expressing uPAR.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ANGSTROM PHARMACEUTICALS INC990 HIGHLAND DRIVE SUITE 314 SOLANA BEACH CA 92075

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Jones, Terence R San Diego, CA 18 314
Mazar, Andrew P La Jolla, CA 24 101

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation